Normal human pituitary gland and pituitary adenomas express cannabinoid receptor type 1 and synthesize endogenous cannabinoids:: First evidence for a direct role of cannabinoids on hormone modulation at the human pituitary level

被引:91
作者
Pagotto, U
Marsicano, G
Fezza, F
Theodoropoulou, M
Grübler, Y
Stalla, J
Arzberger, T
Milone, A
Losa, M
Di Marzo, V
Lutz, B
Stalla, GK
机构
[1] Max Planck Inst Psychiat, Neuroendocrinol Grp, D-80804 Munich, Germany
[2] Max Planck Inst Psychiat, Mol Genet Behav Grp, D-80804 Munich, Germany
[3] CNR, Ist Chim Mol Interesse Biol, Endocannabinoid Res Grp, I-80072 Arco Felice Napoli, Italy
[4] Hosp San Raffaele, Dept Neurosurg, I-20132 Milan, Italy
关键词
D O I
10.1210/jc.86.6.2687
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Little is known about the expression and function of cannabinoid receptor type 1 (CB1) in the human pituitary gland. The aim of this study was to investigate CB1 expression in human normal and tumoral pituitaries by in situ hybridization and immunohistochemistry using an antibody against CB1. CB1 was found in corticotrophs, mammotrophs, somatotrophs, and folliculostellate cells in the anterior lobe of normal pituitary. After examination of 42 pituitary adenomas, CB1 was detected in acromegaly-associated pituitary adenomas, Cushing's adenomas, and prolactinomas, whereas faint or no expression was found in nonfunctioning pituitary adenomas. Experiments with cultured pituitary adenoma cells showed that the CB1 agonist WIN 55,212-2 inhibited GH secretion in most of acromegaly-associated pituitary adenomas tested and that the GB 1 antagonist SR 141716A was generally able to reverse this effect. Moreover, WIN 55,212-2 was able to suppress GHRH-stimulated GH release, and this effect was not blocked by coincubation with SR 141716A, possibly indicating a non-CB1-mediated effect. In contrast, WIN 55,212-2 was ineffective on GH-releasing peptide-stimulated GH release. In four Cushing's adenomas tested, WIN 55,212-2 was not able to modify basal ACTH secretion. However, simultaneous application of CRF and WIN 55,212-2 resulted in a synergistic effect on ACTH secretion, and this effect could be abolished by SR 141716A, demonstrating a CB1-mediated effect. In the single case of prolactinomas tested, WIN 55,212-2 was able to inhibit basal secretion of PRL. Finally, the presence of endocannabinoids (anandamide and 2-arachidonoylglycerol) was investigated in normal and tumoral pituitaries. All tumoral samples had higher contents of anandamide and 2-arachidonoylglycerol compared with the normal hypophysis. Moreover, endocannabinoid content in the different pituitary adenomas correlated with the presence of CB1, being elevated in the tumoral samples positive for CB1 and lower in the samples in which no or low levels of CB1 were found. The results of this study point to a direct role of cannabinoids in the regulation of human pituitary hormone secretion.
引用
收藏
页码:2687 / 2696
页数:10
相关论文
共 43 条
[21]   DELTA-9-TETRAHYDROCANNABINOL SUPPRESSION OF PROLACTIN SECRETION IN THE RAT - LACK OF DIRECT PITUITARY EFFECT [J].
HUGHES, CL ;
EVERETT, JW ;
TYREY, L .
ENDOCRINOLOGY, 1981, 109 (03) :876-880
[22]   Role of the hypothalamic-pituitary-adrenal axis in the suppression of luteinizing hormone release by delta-9-tetrahydrocannabinol [J].
Jackson, AL ;
Murphy, LL .
NEUROENDOCRINOLOGY, 1997, 65 (06) :446-452
[23]   CORTICOSTERONE ELEVATION MEDIATED CENTRALLY BY DELTA-1-TETRAHYDROCANNABINOL IN RATS [J].
KUBENA, RK ;
PERHACH, JL ;
BARRY, H .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1971, 14 (01) :89-&
[24]   Paradoxical action of the cannabinoid WIN 55,212-2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices [J].
Maneuf, YP ;
Brotchie, JM .
BRITISH JOURNAL OF PHARMACOLOGY, 1997, 120 (08) :1397-1398
[25]  
Martin B R, 1994, Adv Pharmacol, V25, P341, DOI 10.1016/S1054-3589(08)60437-8
[26]   Suppression of nerve growth factor trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation [J].
Melck, D ;
De Petrocellis, L ;
Orlando, P ;
Bisogno, T ;
Laezza, C ;
Bifulco, M ;
Di Marzo, V .
ENDOCRINOLOGY, 2000, 141 (01) :118-126
[27]   EFFECTS OF DELTA-9-TETRAHYDROCANNABINOL, CANNABINOL AND CANNABIDIOL, ALONE AND IN COMBINATIONS, ON LUTEINIZING-HORMONE AND PROLACTIN-RELEASE AND ON HYPOTHALAMIC NEUROTRANSMITTERS IN THE MALE-RAT [J].
MURPHY, LL ;
STEGER, RW ;
SMITH, MS ;
BARTKE, A .
NEUROENDOCRINOLOGY, 1990, 52 (04) :316-321
[28]   Function of cannabinoid receptors in the neuroendocrine regulation of hormone secretion [J].
Murphy, LL ;
Muñoz, RM ;
Adrian, BA ;
Villanúa, MA .
NEUROBIOLOGY OF DISEASE, 1998, 5 (06) :432-446
[29]   EXPRESSION AND LOCALIZATION OF ENDOTHELIN-1 AND ENDOTHELIN RECEPTORS IN HUMAN MENINGIOMAS - EVIDENCE FOR A ROLE IN TUMORAL GROWTH [J].
PAGOTTO, U ;
ARZBERGER, T ;
HOPFNER, U ;
SAUER, J ;
RENNER, U ;
NEWTON, CJ ;
LANGE, M ;
UHL, E ;
WEINDL, A ;
STALLA, GK .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 96 (04) :2017-2025
[30]  
Pagotto U, 2000, CANCER RES, V60, P6794